LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 72.27 | 770.25 | 10203 | 10730 | 0.9508 | 0.9736 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 74.50 | 770.25 | 10634 | 10991 | 0.9675 | 0.9828 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 74.50 | 770.25 | 10301 | 10991 | 0.9372 | 0.9664 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 76.75 | 770.25 | 10848 | 11262 | 0.9632 | 0.9807 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 76.75 | 770.25 | 10457 | 11262 | 0.9285 | 0.9620 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 78.98 | 770.25 | 11205 | 11518 | 0.9728 | 0.9859 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 78.98 | 770.25 | 10577 | 11518 | 0.9183 | 0.9568 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 81.20 | 770.25 | 11528 | 11766 | 0.9797 | 0.9896 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 81.20 | 770.25 | 10804 | 11766 | 0.9182 | 0.9571 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 83.42 | 770.25 | 11921 | 12031 | 0.9908 | 0.9953 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 83.42 | 770.25 | 10979 | 12031 | 0.9125 | 0.9543 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 85.64 | 770.25 | 12208 | 12287 | 0.9935 | 0.9968 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 85.64 | 770.25 | 11136 | 12287 | 0.9063 | 0.9514 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 87.86 | 770.25 | 12610 | 12543 | 1.0053 | 1.0026 | MN20160304_L02 | F15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.01 | 87.86 | 770.25 | 11323 | 12543 | 0.9027 | 0.9498 | MN20160304_L02 | N08 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 3.21 | 770.25 | 844 | 904 | 0.9330 | 0.4831 | MN20160304_L02 | E19 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 3.21 | 770.25 | 962 | 904 | 1.0634 | 1.6070 | MN20160304_L02 | I17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 5.44 | 770.25 | 940 | 1012 | 0.9282 | 0.6559 | MN20160304_L02 | E19 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 5.44 | 770.25 | 1087 | 1012 | 1.0733 | 1.3925 | MN20160304_L02 | I17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 7.66 | 770.25 | 1023 | 1090 | 0.9385 | 0.7621 | MN20160304_L02 | E19 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 7.66 | 770.25 | 1199 | 1090 | 1.1000 | 1.4191 | MN20160304_L02 | I17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 10.06 | 770.25 | 1132 | 1218 | 0.9290 | 0.7894 | MN20160304_L02 | E19 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 10.06 | 770.25 | 1328 | 1218 | 1.0899 | 1.2778 | MN20160304_L02 | I17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 12.28 | 770.25 | 1264 | 1358 | 0.9307 | 0.8319 | MN20160304_L02 | E19 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.018333 | 12.28 | 770.25 | 1490 | 1358 | 1.0971 | 1.2398 | MN20160304_L02 | I17 |